;PMID: 7742153
;source_file_938.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..177] = [t:48..177]
;2)section:[e:181..263] = [t:181..263]
;3)section:[e:267..331] = [t:267..331]
;4)sentence:[e:335..506] = [t:335..506]
;5)sentence:[e:507..820] = [t:507..820]
;6)sentence:[e:821..1015] = [t:821..1015]
;7)sentence:[e:1017..1147] = [t:1017..1147]
;8)sentence:[e:1148..1472] = [t:1148..1472]
;9)sentence:[e:1473..1555] = [t:1473..1555]
;10)sentence:[e:1556..1703] = [t:1556..1703]
;11)sentence:[e:1704..1973] = [t:1704..1973]
;12)sentence:[e:1974..2102] = [t:1974..2102]
;13)section:[e:2106..2150] = [t:2106..2150]

;section 0 Span:0..42
;Br J Clin Pharmacol. 1995 Feb;39(2):151-9.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..9] Clin)
        (NNP:[10..19] Pharmacol) (.:[19..20] .) (CD:[21..25] 1995)
        (.:[26..33] Feb;39-LRB-) (CD:[33..34] 2) (-RRB-:[34..35] -RRB-)
        (CD:[35..39] :151) (::[39..40] -) (CD:[40..42] 9.)))

;sentence 1 Span:48..177
;Selective serotonin reuptake inhibitors and theophylline metabolism in human 
;liver microsomes: potent inhibition by fluvoxamine.
;[48..87]:substance:"Selective serotonin reuptake inhibitors"
;[92..104]:substance:"theophylline"
;[165..176]:substance:"fluvoxamine"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (JJ:[48..57] Selective)
          (NML (NN:[58..67] serotonin) (NN:[68..76] reuptake))
          (NNS:[77..87] inhibitors))
        (CC:[88..91] and)
        (NP (NN:[92..104] theophylline) (NN:[105..115] metabolism)))
      (PP-LOC (IN:[116..118] in)
        (NP (JJ:[119..124] human) (NN:[126..131] liver)
            (NNS:[132..142] microsomes))))
    (::[142..143] :)
    (NP
      (NP (JJ:[144..150] potent) (NN:[151..161] inhibition))
      (PP-MNR (IN:[162..164] by)
        (NP (NN:[165..176] fluvoxamine))))
    (.:[176..177] .)))

;section 2 Span:181..263
;Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J,
;Brosen  K.
(SEC
  (FRAG (NNP:[181..190] Rasmussen) (NNP:[191..193] BB) (,:[193..194] ,)
        (NNP:[195..202] Maenpaa) (NNP:[203..205] J,) (NNP:[206..214] Pelkonen)
        (NNP:[215..216] O) (,:[216..217] ,) (NNP:[218..222] Loft)
        (NNP:[223..225] S,) (NNP:[226..233] Poulsen) (NNP:[234..236] HE)
        (,:[236..237] ,) (NNP:[238..249] Lykkesfeldt) (NNP:[250..252] J,)
        (NNP:[253..259] Brosen) (NNP:[261..263] K.)))

;section 3 Span:267..331
;Department of Clinical Pharmacology, Odense University, Denmark.
(SEC
  (FRAG (NNP:[267..277] Department) (IN:[278..280] of) (NNP:[281..289] Clinical)
        (NNP:[290..302] Pharmacology) (,:[302..303] ,) (NNP:[304..310] Odense)
        (NNP:[311..321] University) (,:[321..322] ,) (NNP:[323..330] Denmark)
        (.:[330..331] .)))

;sentence 4 Span:335..506
;1. Fluvoxamine and seven other selective serotonin reuptake inhibitors (SRRI)
; were tested for their ability to inhibit a number of human cytochrome P450 
;isoforms (CYPs).
;[338..349]:substance:"Fluvoxamine"
;[366..405]:substance:"selective serotonin reuptake inhibitors"
;[407..411]:substance:"SRRI"
;[473..498]:cyp450:"cytochrome P450  isoforms"
;[500..504]:cyp450:"CYPs"
(SENT
  (NP (LS:[335..337] 1.))
  (S
    (NP-SBJ-1
      (NP (NN:[338..349] Fluvoxamine))
      (CC:[350..353] and)
      (NP
        (NP (CD:[354..359] seven) (JJ:[360..365] other)
           (JJ:[366..375] selective)
          (NML (NN:[376..385] serotonin) (NN:[386..394] reuptake))
          (NNS:[395..405] inhibitors))
        (NP (-LRB-:[406..407] -LRB-) (NN:[407..411] SRRI)
            (-RRB-:[411..412] -RRB-))))
    (VP (VBD:[414..418] were)
      (VP (VBN:[419..425] tested)
        (NP-1 (-NONE-:[425..425] *))
        (PP (IN:[426..429] for)
          (NP (PRP$:[430..435] their) (NN:[436..443] ability)
            (S
              (NP-SBJ (-NONE-:[443..443] *))
              (VP (TO:[444..446] to)
                (VP (VB:[447..454] inhibit)
                  (NP
                    (NP (DT:[455..456] a) (NN:[457..463] number))
                    (PP (IN:[464..466] of)
                      (NP
                        (NP (JJ:[467..472] human)
                          
                          (NML (NN:[473..483] cytochrome) (NN:[484..488] P450))
                          (NNS:[490..498] isoforms))
                        (NP (-LRB-:[499..500] -LRB-) (NNS:[500..504] CYPs)
                            (-RRB-:[504..505] -RRB-))))))))))))
    (.:[505..506] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[335..506]::NP:S:

;sentence 5 Span:507..820
;2. None of the drugs showed potent inhibition of CYP2A6  (coumarin
;7-hydroxylase) or CYP2E1 (chlorzoxazone 6-hydroxylase), while  norfluoxetine
;was the only potent inhibitor of CYP3A having IC50 values of 11  microM and
;19 microM for testosterone 6 beta-hydroxylase and cortisol 6 
;beta-hydroxylase, respectively.
;[522..527]:substance:"drugs"
;[556..562]:cyp450:"CYP2A6"
;[565..587]:cyp450:"coumarin 7-hydroxylase"
;[592..598]:cyp450:"CYP2E1"
;[600..627]:cyp450:"chlorzoxazone 6-hydroxylase"
;[637..650]:substance:"norfluoxetine"
;[671..680]:substance:"inhibitor"
;[684..689]:cyp450:"CYP3A"
;[697..701]:quantitative-name:"IC50"
;[712..714]:quantitative-value:"11"
;[716..722]:quantitative-units:"microM"
;[727..729]:quantitative-value:"19"
;[730..736]:quantitative-units:"microM"
;[741..772]:substance:"testosterone 6 beta-hydroxylase"
;[777..805]:substance:"cortisol 6  beta-hydroxylase"
(SENT
  (NP (LS:[507..509] 2.))
  (S
    (NP-SBJ
      (NP (NN:[510..514] None))
      (PP (IN:[515..517] of)
        (NP (DT:[518..521] the) (NNS:[522..527] drugs))))
    (VP (VBD:[528..534] showed)
      (NP
        (NP (JJ:[535..541] potent) (NN:[542..552] inhibition))
        (PP (IN:[553..555] of)
          (NP
            (NP
              (NP (NN:[556..562] CYP2A6))
              (NP (-LRB-:[564..565] -LRB-)
                 (NN:[565..573] coumarin) (NN:[574..587] 7-hydroxylase)
                (-RRB-:[587..588] -RRB-)))
            (CC:[589..591] or)
            (NP
              (NP (NN:[592..598] CYP2E1))
              (NP (-LRB-:[599..600] -LRB-)
                 (NN:[600..613] chlorzoxazone) (NN:[614..627] 6-hydroxylase)
                (-RRB-:[627..628] -RRB-))))))
      (,:[628..629] ,)
      (SBAR-ADV (IN:[630..635] while)
        (S
          (NP-SBJ (NN:[637..650] norfluoxetine))
          (VP (VBD:[651..654] was)
            (NP-PRD
              (VP
                (NP (DT:[655..658] the) (RB:[659..663] only)
                    (JJ:[664..670] potent) (NN:[671..680] inhibitor))
                (PP (IN:[681..683] of)
                  (NP (NN:[684..689] CYP3A))))
              (VP (VBG:[690..696] having)
                (NP
                  (NP (NN:[697..701] IC50) (NNS:[702..708] values))
                  (PP (IN:[709..711] of)
                    (NP
                      (NP (CD:[712..714] 11) (NN:[716..722] microM))
                      (CC:[723..726] and)
                      (NP (CD:[727..729] 19) (NN:[730..736] microM))))
                  (PP (IN:[737..740] for)
                    (NP
                      (NP (NN:[741..753] testosterone) (CD:[754..755] 6)
                          (NN:[756..772] beta-hydroxylase))
                      (CC:[773..776] and)
                      (NP (NN:[777..785] cortisol) (CD:[786..787] 6)
                          (NN:[789..805] beta-hydroxylase)))))
                (,:[805..806] ,)
                (ADVP (RB:[807..819] respectively))))))))
    (.:[819..820] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[507..820]::NP:S:

;sentence 6 Span:821..1015
;3. Norfluoxetine, sertraline and fluvoxamine  inhibited CYP1A1
;(7-ethoxyresorufin O-deethylase) in microsomes from human  placenta (IC50
;values 29 microM, 35 microM and 80 microM, respectively).
;[824..837]:substance:"Norfluoxetine"
;[839..849]:substance:"sertraline"
;[854..865]:substance:"fluvoxamine"
;[877..883]:cyp450:"CYP1A1"
;[885..915]:cyp450:"7-ethoxyresorufin O-deethylase"
;[953..957]:quantitative-name:"IC50"
;[965..967]:quantitative-value:"29"
;[968..974]:quantitative-units:"microM"
;[976..978]:quantitative-value:"35"
;[979..985]:quantitative-units:"microM"
;[990..992]:quantitative-value:"80"
;[993..999]:quantitative-units:"microM"
(SENT
  (NP (LS:[821..823] 3.))
  (S
    (NP-SBJ (NN:[824..837] Norfluoxetine) (,:[837..838] ,)
            (NN:[839..849] sertraline) (CC:[850..853] and)
            (NN:[854..865] fluvoxamine))
    (VP (VBD:[867..876] inhibited)
      (NP
        (NP (NN:[877..883] CYP1A1))
        (NP (-LRB-:[884..885] -LRB-)
           (NN:[885..902] 7-ethoxyresorufin) (NN:[903..915] O-deethylase)
          (-RRB-:[915..916] -RRB-)))
      (PP-LOC (IN:[917..919] in)
        (NP
          (NP (NNS:[920..930] microsomes))
          (PP (IN:[931..935] from)
            (NP (JJ:[936..941] human) (NN:[943..951] placenta)))
          (PRN (-LRB-:[952..953] -LRB-)
            (FRAG
              (NP-SBJ (NN:[953..957] IC50) (NNS:[958..964] values))
              (NP-PRD
                (NP (CD:[965..967] 29) (NN:[968..974] microM))
                (,:[974..975] ,)
                (NP (CD:[976..978] 35) (NN:[979..985] microM))
                (CC:[986..989] and)
                (NP (CD:[990..992] 80) (NN:[993..999] microM)))
              (,:[999..1000] ,)
              (ADVP (RB:[1001..1013] respectively)))
            (-RRB-:[1013..1014] -RRB-)))))
    (.:[1014..1015] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[821..1015]::NP:S:

;sentence 7 Span:1017..1147
;Fluvoxamine was a potent inhibitor of CYP1A2-mediated 7-ethoxyresorufin 
;O-deethylase activity (IC50 = 0.3 microM) in human liver.
;[1017..1028]:substance:"Fluvoxamine"
;[1042..1051]:substance:"inhibitor"
;[1055..1061]:cyp450:"CYP1A2"
;[1071..1102]:cyp450:"7-ethoxyresorufin  O-deethylase"
;[1113..1117]:quantitative-name:"IC50"
;[1120..1123]:quantitative-value:"0.3"
;[1124..1130]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1017..1028] Fluvoxamine))
    (VP (VBD:[1029..1032] was)
      (NP-PRD
        (NP (DT:[1033..1034] a) (JJ:[1035..1041] potent)
            (NN:[1042..1051] inhibitor))
        (PP (IN:[1052..1054] of)
          (NP
            (ADJP (NN:[1055..1061] CYP1A2) (HYPH:[1061..1062] -)
                  (VBN:[1062..1070] mediated))
            (NML (NN:[1071..1088] 7-ethoxyresorufin)
                 (NN:[1090..1102] O-deethylase))
            (NN:[1103..1111] activity)))
        (PRN (-LRB-:[1112..1113] -LRB-)
          (S
            (NP-SBJ (NN:[1113..1117] IC50))
            (VP (SYM:[1118..1119] =)
              (NP (CD:[1120..1123] 0.3) (NN:[1124..1130] microM))))
          (-RRB-:[1130..1131] -RRB-)))
      (PP-LOC (IN:[1132..1134] in)
        (NP (JJ:[1135..1140] human) (NN:[1141..1146] liver))))
    (.:[1146..1147] .)))

;sentence 8 Span:1148..1472
;4. In microsomes from  three human livers fluvoxamine potently inhibited all
;pathways of theophylline  biotransformation, the apparent inhibitor constant,
;Ki, was 0.07-0.13 microM,  0.05-0.10 microM and 0.16-0.29 microM for
;inhibition of 1-methylxanthine,  3-methylxanthine and 1,3-dimethyluric acid
;formation, respectively.
;[1190..1201]:substance:"fluvoxamine"
;[1237..1249]:substance:"theophylline"
;[1283..1292]:substance:"inhibitor"
;[1303..1305]:quantitative-name:"Ki"
;[1311..1320]:quantitative-value:"0.07-0.13"
;[1321..1327]:quantitative-units:"microM"
;[1330..1339]:quantitative-value:"0.05-0.10"
;[1340..1346]:quantitative-units:"microM"
;[1351..1360]:quantitative-value:"0.16-0.29"
;[1361..1367]:quantitative-units:"microM"
;[1386..1402]...[1443..1447]:substance:"1-methylxanthine"..."acid"
;[1405..1421]...[1443..1447]:substance:"3-methylxanthine"..."acid"
;[1426..1447]:substance:"1,3-dimethyluric acid"
(SENT
  (NP (LS:[1148..1150] 4.))
  (S
    (S
      (PP-LOC (IN:[1151..1153] In)
        (NP
          (NP (NNS:[1154..1164] microsomes))
          (PP (IN:[1165..1169] from)
            (NP (CD:[1171..1176] three) (JJ:[1177..1182] human)
                (NNS:[1183..1189] livers)))))
      (NP-SBJ (NN:[1190..1201] fluvoxamine))
      (ADVP (RB:[1202..1210] potently))
      (VP (VBD:[1211..1220] inhibited)
        (NP
          (NP (DT:[1221..1224] all) (NNS:[1225..1233] pathways))
          (PP (IN:[1234..1236] of)
            (NP (NN:[1237..1249] theophylline)
                (NN:[1251..1268] biotransformation))))))
    (,:[1268..1269] ,)
    (NP-SBJ
      (NP (DT:[1270..1273] the) (JJ:[1274..1282] apparent)
          (NN:[1283..1292] inhibitor) (NN:[1293..1301] constant))
      (,:[1301..1302] ,)
      (NP (NN:[1303..1305] Ki)))
    (,:[1305..1306] ,)
    (VP (VBD:[1307..1310] was)
      (NP-PRD
        (NP
          (QP (CD:[1311..1315] 0.07) (HYPH:[1315..1316] -)
              (CD:[1316..1320] 0.13))
          (NN:[1321..1327] microM))
        (,:[1327..1328] ,)
        (NP
          (QP (CD:[1330..1334] 0.05) (HYPH:[1334..1335] -)
              (CD:[1335..1339] 0.10))
          (NN:[1340..1346] microM))
        (CC:[1347..1350] and)
        (NP
          (QP (CD:[1351..1355] 0.16) (HYPH:[1355..1356] -)
              (CD:[1356..1360] 0.29))
          (NN:[1361..1367] microM)))
      (PP (IN:[1368..1371] for)
        (NP
          (NP (NN:[1372..1382] inhibition))
          (PP (IN:[1383..1385] of)
            (NP
              (NP (NN:[1386..1402] 1-methylxanthine)
                (NML-1 (-NONE-:[1402..1402] *P*)))
              (,:[1402..1403] ,)
              (NP (NN:[1405..1421] 3-methylxanthine)
                (NML-1 (-NONE-:[1421..1421] *P*)))
              (CC:[1422..1425] and)
              (NP
                 (JJ:[1426..1442] 1,3-dimethyluric) (NN:[1443..1447] acid)
                (NML-1 (NN:[1448..1457] formation)))
              (,:[1457..1458] ,)
              (ADVP (RB:[1459..1471] respectively)))))))
    (.:[1471..1472] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1148..1472]::NP:S:

;sentence 9 Span:1473..1555
;Seven other  SSRIs showed either weak or no inhibition of theophylline
;metabolism.
;[1486..1491]:substance:"SSRIs"
;[1531..1543]:substance:"theophylline"
(SENT
  (S
    (NP-SBJ (CD:[1473..1478] Seven) (JJ:[1479..1484] other)
            (NNS:[1486..1491] SSRIs))
    (VP (VBD:[1492..1498] showed)
      (NP
        (NP (CC:[1499..1505] either)
          (NP (JJ:[1506..1510] weak)
            (NML-1 (-NONE-:[1510..1510] *P*)))
          (CC:[1511..1513] or)
          (NP (DT:[1514..1516] no)
            (NML-1 (NN:[1517..1527] inhibition))))
        (PP (IN:[1528..1530] of)
          (NP (NN:[1531..1543] theophylline) (NN:[1544..1554] metabolism)))))
    (.:[1554..1555] .)))

;sentence 10 Span:1556..1703
;5. Ethanol  inhibited the formation of 1,3-dimethyluric acid with K(i) value
;of 300 microM,  a value which is consistent with inhibition of CYP2E1.
;[1559..1566]:substance:"Ethanol"
;[1595..1616]:substance:"1,3-dimethyluric acid"
;[1622..1626]:quantitative-name:"K(i)"
;[1636..1639]:quantitative-value:"300"
;[1640..1646]:quantitative-units:"microM"
;[1696..1702]:cyp450:"CYP2E1"
(SENT
  (NP (LS:[1556..1558] 5.))
  (S
    (NP-SBJ (NN:[1559..1566] Ethanol))
    (VP (VBD:[1568..1577] inhibited)
      (NP
        (NP (DT:[1578..1581] the) (NN:[1582..1591] formation))
        (PP (IN:[1592..1594] of)
          (NP (JJ:[1595..1611] 1,3-dimethyluric) (NN:[1612..1616] acid))))
      (PP (IN:[1617..1621] with)
        (NP
          (NP
            (NP (NN:[1622..1626] K-LRB-i-RRB-) (NN:[1627..1632] value))
            (PP (IN:[1633..1635] of)
              (NP (CD:[1636..1639] 300) (NN:[1640..1646] microM))))
          (,:[1646..1647] ,)
          (NP
            (NP (DT:[1649..1650] a) (NN:[1651..1656] value))
            (SBAR
              (WHNP-1 (WDT:[1657..1662] which))
              (S
                (NP-SBJ-1 (-NONE-:[1662..1662] *T*))
                (VP (VBZ:[1663..1665] is)
                  (ADJP-PRD (JJ:[1666..1676] consistent)
                    (PP (IN:[1677..1681] with)
                      (NP
                        (NP (NN:[1682..1692] inhibition))
                        (PP (IN:[1693..1695] of)
                          (NP (NN:[1696..1702] CYP2E1)))))))))))))
    (.:[1702..1703] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1556..1703]::NP:S:

;sentence 11 Span:1704..1973
;Ethanol and fluvoxamine  both inhibited 8-hydroxylation by about 45% and, in
;combination, the compounds  decreased the formation of 1,3-dimethyluric acid
;by 90%, indicating that CYP1A2  and CYP2E1 are equally important isoforms for
;the 8-hydroxylation of  theophylline.
;[1704..1711]:substance:"Ethanol"
;[1716..1727]:substance:"fluvoxamine"
;[1769..1772]:quantitative-value:"45%"
;[1798..1807]:substance:"compounds"
;[1836..1857]:substance:"1,3-dimethyluric acid"
;[1861..1864]:quantitative-value:"90%"
;[1882..1888]:cyp450:"CYP1A2"
;[1894..1900]:cyp450:"CYP2E1"
;[1923..1931]:cyp450:"isoforms"
;[1960..1972]:substance:"theophylline"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1704..1711] Ethanol) (CC:[1712..1715] and)
            (NN:[1716..1727] fluvoxamine))
        (NP (CC:[1729..1733] both)))
      (VP (VBD:[1734..1743] inhibited)
        (NP (NN:[1744..1759] 8-hydroxylation))
        (PP-EXT (IN:[1760..1762] by)
          (NP
            (QP (RB:[1763..1768] about) (CD:[1769..1771] 45))
            (NN:[1771..1772] %)))))
    (CC:[1773..1776] and) (,:[1776..1777] ,)
    (S
      (PP (IN:[1778..1780] in)
        (NP (NN:[1781..1792] combination)))
      (,:[1792..1793] ,)
      (NP-SBJ (DT:[1794..1797] the) (NNS:[1798..1807] compounds))
      (VP (VBD:[1809..1818] decreased)
        (NP
          (NP (DT:[1819..1822] the) (NN:[1823..1832] formation))
          (PP (IN:[1833..1835] of)
            (NP (NN:[1836..1852] 1,3-dimethyluric) (NN:[1853..1857] acid))))
        (PP-EXT (IN:[1858..1860] by)
          (NP (CD:[1861..1863] 90) (NN:[1863..1864] %)))
        (,:[1864..1865] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1865..1865] *))
          (VP (VBG:[1866..1876] indicating)
            (SBAR (IN:[1877..1881] that)
              (S
                (NP-SBJ (NN:[1882..1888] CYP1A2) (CC:[1890..1893] and)
                        (NN:[1894..1900] CYP2E1))
                (VP (VBP:[1901..1904] are)
                  (NP-PRD
                    (ADJP (RB:[1905..1912] equally) (JJ:[1913..1922] important))
                    (NNS:[1923..1931] isoforms))
                  (PP (IN:[1932..1935] for)
                    (NP
                      (NP (DT:[1936..1939] the)
                          (NN:[1940..1955] 8-hydroxylation))
                      (PP (IN:[1956..1958] of)
                        (NP (NN:[1960..1972] theophylline))))))))))))
    (.:[1972..1973] .)))

;sentence 12 Span:1974..2102
;6. It is concluded that pharmacokinetic interaction between  fluvoxamine and
;theophylline is due to potent inhibition of CYP1A2.
;[2035..2046]:substance:"fluvoxamine"
;[2051..2063]:substance:"theophylline"
;[2095..2101]:cyp450:"CYP1A2"
(SENT
  (NP (LS:[1974..1976] 6.))
  (S
    (NP-SBJ-1
      (NP (PRP:[1977..1979] It))
      (SBAR-2 (-NONE-:[1979..1979] *EXP*)))
    (VP (VBZ:[1980..1982] is)
      (VP (VBN:[1983..1992] concluded)
        (NP-1 (-NONE-:[1992..1992] *))
        (SBAR-2 (IN:[1993..1997] that)
          (S
            (NP-SBJ
              (NP (JJ:[1998..2013] pharmacokinetic)
                  (NN:[2014..2025] interaction))
              (PP (IN:[2026..2033] between)
                (NP (NN:[2035..2046] fluvoxamine) (CC:[2047..2050] and)
                    (NN:[2051..2063] theophylline))))
            (VP (VBZ:[2064..2066] is)
              (PP-PRD (IN:[2067..2070] due)
                (PP (TO:[2071..2073] to)
                  (NP
                    (NP (JJ:[2074..2080] potent) (NN:[2081..2091] inhibition))
                    (PP (IN:[2092..2094] of)
                      (NP (NN:[2095..2101] CYP1A2)))))))))))
    (.:[2101..2102] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1974..2102]::NP:S:

;section 13 Span:2106..2150
;PMID: 7742153 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2106..2110] PMID) (::[2110..2111] :) (CD:[2112..2119] 7742153)
        (NN:[2120..2121] -LSB-) (NNP:[2121..2127] PubMed) (::[2128..2129] -)
        (NN:[2130..2137] indexed) (IN:[2138..2141] for)
        (NNP:[2142..2150] MEDLINE-RSB-)))
